Perrigo gaps up after results, guidance, levels to watch The shares are up over 5.5% at time of writing, which is closer to the lows of the session so far. The company beat consensus expectations for its Q2 when it reported earnings of $1.36, 5 cents higher than estimated. Resistance is at $107.48. Support is at the session low at $105.05.
Galmed and Perrigo sign agreement for aramchol API production Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.